中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

56 records (took 0.019 seconds)

    INHIBITION OF THE FORMATION OF VASCULAR HYPERPERMEABILITY
    33.
    发明专利
    INHIBITION OF THE FORMATION OF VASCULAR HYPERPERMEABILITY 未知

    公开(公告)号：CA2347916A1

    公开(公告)日：2000-05-18

    申请号：CA2347916

    申请日：1999-11-03

    Applicant: BASF AG

    Inventor： ARNOLD LEE D ,  BOUSQUET PETER F

    IPC: A61K45/00 ,  A61K31/7105 ,  A61K38/00 ,  A61K38/17 ,  A61K38/19 ,  A61K39/395 ,  A61K48/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/10 ,  A61P9/00 ,  A61P9/02 ,  A61P9/10 ,  A61P11/06 ,  A61P11/16 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/02 ,  A61P19/00 ,  A61P27/00 ,  A61P27/06 ,  A61P27/12 ,  A61P29/00 ,  A61P35/00 ,  A61P37/08 ,  A61P43/00 ,  C07K14/71 ,  A61K31/415

    Abstract: Vascular hyperpermeability and the subsequent events such as macular edema, retinoblastoma, ocular ischemia, ocular inflammatory disease or infection, choroidal melanoma, edematous side-effects induced by iron chelation therapy , pulmonary edema, myocardial infarction, rheumatoid diseases, anaphylaxis, allergies, hypersensitive reactions, cerebral edema, brain tumor fluid-fille d cysts, communicating hydrocephalus, carpal tunnel syndrome, organ damage resulting from a burn, irritation or infection, erythema multiforme, edemato us macules and other disorders, brain tumors, tumor effusions, lung or breast carcinomas, ascites, pleural effusions, pericardial effusions, high altitude "sickness", radioanaphylaxis, radiodermatitis, glaucoma, conjunctivitis, choroidal melanoma, adult respiratory distress syndrome, asthma, bronchitis, ovarian hyperstimulation syndrome, polycystic ovary syndrome, menstrual swelling, menstrual cramps, stroke, head trauma, cerebral infarct or occlusion, hyotension, ulcerations, sprains, fractures, effusions associated with synovitis, diabetic complications, hyperviscosity syndrome, liver cirrhosis, microalbuminuria, proteinuria, oliguria, electrolyte imbalance, nephrotic syndrome, exudates, fibroses, keloid, can be inhibited by the administration of a compound that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. The preferred compoun d 4,5-dihydro-3-pyridin-4-yl-1(2)H-benzo[g]indazole selectively inhibits the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGE tyrosine kinase receptor.

    INHIBITION OF THE FORMATION OF VASCULAR HYPERPERMEABILITY
    36.
    发明专利
    INHIBITION OF THE FORMATION OF VASCULAR HYPERPERMEABILITY 未知

    公开(公告)号：PL348163A1

    公开(公告)日：2002-05-06

    申请号：PL34816399

    申请日：1999-11-03

    Applicant: BASF AG

    Inventor： ARNOLD LEE D ,  BOUSQUET PETER F

    IPC: A61K45/00 ,  A61K31/7105 ,  A61K38/00 ,  A61K38/17 ,  A61K38/19 ,  A61K39/395 ,  A61K48/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/10 ,  A61P9/00 ,  A61P9/02 ,  A61P9/10 ,  A61P11/06 ,  A61P11/16 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/02 ,  A61P19/00 ,  A61P27/00 ,  A61P27/06 ,  A61P27/12 ,  A61P29/00 ,  A61P35/00 ,  A61P37/08 ,  A61P43/00 ,  C07K14/71

    Abstract: Vascular hyperpermeability and the subsequent events such as macular edema, retinoblastoma, ocular ischemia, ocular inflammatory disease or infection, choroidal melanoma, edematous side-effects induced by iron chelation therapy, pulmonary edema, myocardial infarction, rheumatoid diseases, anaphylaxis, allergies, hypersensitive reactions, cerebral edema, brain tumor fluid-filled cysts, communicating hydrocephalus, carpal tunnel syndrome, organ damage resulting from a burn, irritation or infection, erythema multiforme, edematous macules and other disorders, brain tumors, tumor effusions, lung or breast carcinomas, ascites, pleural effusions, pericardial effusions, high altitude "sickness", radioanaphylaxis, radiodermatitis, glaucoma, conjunctivitis, choroidal melanoma, adult respiratory distress syndrome, asthma, bronchitis, ovarian hyperstimulation syndrome, polycystic ovary syndrome, menstrual swelling, menstrual cramps, stroke, head trauma, cerebral infarct or occlusion, hyotension, ulcerations, sprains, fractures, effusions associated with synovitis, diabetic complications, hyperviscosity syndrome, liver cirrhosis, microalbuminuria, proteinuria, oliguria, electrolyte imbalance, nephrotic syndrome, exudates, fibroses, keloid, can be inhibited by the administration of a compound that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. The preferred compound 4,5-dihydro-3-pyridin-4-yl-1(2)H-benzo[g]indazole selectively inhibits the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGE tyrosine kinase receptor.

Patent Agency Ranking